<p>擁有大量資金的投資者對 <strong>禮來</strong> (NYSE: LLY) 持悲觀態度。</p>
<p>而散户交易者應該知道這一點。</p>
<p>我們今天注意到這一點，當交易出現在我們在 Benzinga 跟蹤的公開可用期權歷史中時。</p>
<p>我們不知道這些是機構還是僅僅是富有的個人。但當 LLY 發生如此重大的事情時，通常意味着有人知道即將發生什麼。</p>
<p>那麼我們如何知道這些投資者剛剛做了什麼呢？</p>
<p>今天，Benzinga 的期權掃描器發現了 33 筆不尋常的禮來期權交易。</p>
<p>這並不正常。</p>
<p>這些大資金交易者的整體情緒在 39% 看漲和 42% 看跌之間分裂。</p>
<p>在我們發現的所有特殊期權中，有 9 筆看跌期權，總金額為 $1,005,471，24 筆看漲期權，總金額為 $1,892,620。</p>
<h3>價格目標是什麼？</h3>
<p>分析這些合約的成交量和未平倉合約，似乎大玩家在過去一個季度內關注禮來的價格區間為 $500.0 到 $1600.0。</p>
<h3>分析成交量和未平倉合約</h3>
<p>在今天的交易背景下，禮來的期權平均未平倉合約為 420.12，總成交量達到 954.00。附帶的圖表描繪了過去 30 天內禮來高價值交易的看漲和看跌期權的成交量和未平倉合約的變化。</p>
<h3>禮來過去 30 天的期權成交量和未平倉合約</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1767366114_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="期權看漲圖表" width="1500" height="800" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1767366114_0.png"/></p>
<h3>觀察到的最大期權交易：</h3>
<table>
<thead>
<tr>
<th><strong>符號</strong></th>
<th><strong>看跌/看漲</strong></th>
<th><strong>交易類型</strong></th>
<th><strong>情緒</strong></th>
<th><strong>到期日</strong></th>
<th><strong>賣出價</strong></th>
<th><strong>買入價</strong></th>
<th><strong>價格</strong></th>
<th><strong>行權價</strong></th>
<th><strong>總交易價格</strong></th>
<th align="right"><strong>未平倉合約</strong></th>
<th align="right"><strong>成交量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>看跌</td>
<td>掃描</td>
<td>看漲</td>
<td>02/13/26</td>
<td>$13.0</td>
<td>$4.75</td>
<td>$7.65</td>
<td>$910.00</td>
<td>$634.3K</td>
<td align="right">0</td>
<td align="right">805</td>
</tr>
<tr>
<td>LLY</td>
<td>看漲</td>
<td>交易</td>
<td>看跌</td>
<td>12/18/26</td>
<td>$588.0</td>
<td>$580.0</td>
<td>$582.75</td>
<td>$500.00</td>
<td>$291.3K</td>
<td align="right">27</td>
<td align="right">5</td>
</tr>
<tr>
<td>LLY</td>
<td>看漲</td>
<td>交易</td>
<td>看漲</td>
<td>09/18/26</td>
<td>$578.05</td>
<td>$571.0</td>
<td>$575.25</td>
<td>$500.00</td>
<td>$287.6K</td>
<td align="right">41</td>
<td align="right">5</td>
</tr>
<tr>
<td>LLY</td>
<td>看漲</td>
<td>交易</td>
<td>看漲</td>
<td>01/15/27</td>
<td>$361.0</td>
<td>$357.4</td>
<td>$361.0</td>
<td>$750.00</td>
<td>$180.5K</td>
<td align="right">376</td>
<td align="right">5</td>
</tr>
<tr>
<td>LLY</td>
<td>看漲</td>
<td>交易</td>
<td>看漲</td>
<td>09/18/26</td>
<td>$236.6</td>
<td>$234.6</td>
<td>$236.6</td>
<td>$900.00</td>
<td>$118.3K</td>
<td align="right">162</td>
<td align="right">6</td>
</tr>
</tbody>
</table>
<h3>關於禮來</h3>
<p>禮來是一家專注於神經科學、心血管代謝、癌症和免疫學的製藥公司。禮來的主要產品包括用於癌症的 Verzenio；用於心血管代謝的 Mounjaro、Zepbound、Jardiance、Trulicity、Humalog 和 Humulin；以及用於免疫學的 Taltz 和 Olumiant。</p>
<p>鑑於禮來的近期期權歷史，現在適合關注公司本身。我們旨在探討其當前表現。</p>
<h3>禮來的當前市場狀況</h3>
<ul>
<li>LLY 的成交量為 331,417，價格下跌 -0.98%，為 $1064.19。</li>
<li>RSI 指標暗示基礎股票可能接近超買狀態。</li>
<li>下一次財報預計將在 34 天后發佈。</li>
</ul>
<h3>專家對禮來的看法</h3>
<p>在過去一個月中，3 位專家對該股票發佈了評級，平均目標價格為 $1222.67。</p>
<p><strong>在短短 20 天內將 $1000 變成 $1270？</strong></p>
<p>一位擁有 20 年經驗的期權交易專家揭示了他的單行圖表技術，顯示何時買入和賣出。複製他的交易，平均每 20 天獲得 27% 的利潤。點擊這裏獲取訪問權限。
* 在評估中保持一致，來自富國銀行的分析師對禮來保持超配評級，目標價格為 $1200。
* 來自 BMO Capital 的分析師對禮來保持跑贏大盤評級，目標價格為 $1200。
* 來自美國銀行證券的分析師對禮來保持買入評級，目標價格為 $1268。</p>
<p>期權是一種比僅交易股票更具風險的資產，但它們具有更高的利潤潛力。嚴肅的期權交易者通過每天學習、逐步進出交易、關注多個指標以及密切關注市場來管理這種風險。</p>
<p>如果您想隨時瞭解禮來的最新期權交易，Benzinga Pro 為您提供實時期權交易警報。</p>

禮來

<p>禮來（NYSE: LLY）近期出現了顯著的看跌期權活動，共檢測到 33 筆異常交易。大型投資者的情緒呈現分歧，39% 看漲，42% 看跌。總交易金額超過 280 萬美元，價格目標範圍為 500 美元至 1600 美元。目前，LLY 的股價下跌 0.98%，報 1064.19 美元，分析師給出的平均目標價為 1222.67 美元。值得注意的評級包括來自富國銀行的 “增持” 和來自 BMO 資本的 “跑贏大盤”，兩者的目標價均為 1200 美元。期權交易風險較高，但提供了更大的盈利潛力</p>

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Eli Lilly</strong> (NYSE: LLY).</p>
<div class="lb-trans"><p>擁有大量資金的投資者對 <strong>禮來</strong> (NYSE: LLY) 持悲觀態度。</p>
</div><p>And retail traders should know.</p>
<div class="lb-trans"><p>而散户交易者應該知道這一點。</p>
</div><p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<div class="lb-trans"><p>我們今天注意到這一點，當交易出現在我們在 Benzinga 跟蹤的公開可用期權歷史中時。</p>
</div><p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LLY, it often means somebody knows something is about to happen.</p>
<div class="lb-trans"><p>我們不知道這些是機構還是僅僅是富有的個人。但當 LLY 發生如此重大的事情時，通常意味着有人知道即將發生什麼。</p>
</div><p>So how do we know what these investors just did?</p>
<div class="lb-trans"><p>那麼我們如何知道這些投資者剛剛做了什麼呢？</p>
</div><p>Today, Benzinga's options scanner spotted 33 uncommon options trades for Eli Lilly.</p>
<div class="lb-trans"><p>今天，Benzinga 的期權掃描器發現了 33 筆不尋常的禮來期權交易。</p>
</div><p>This isn't normal.</p>
<div class="lb-trans"><p>這並不正常。</p>
</div><p>The overall sentiment of these big-money traders is split between 39% bullish and 42%, bearish.</p>
<div class="lb-trans"><p>這些大資金交易者的整體情緒在 39% 看漲和 42% 看跌之間分裂。</p>
</div><p>Out of all of the special options we uncovered, 9 are puts, for a total amount of $1,005,471, and 24 are calls, for a total amount of $1,892,620.</p>
<div class="lb-trans"><p>在我們發現的所有特殊期權中，有 9 筆看跌期權，總金額為 $1,005,471，24 筆看漲期權，總金額為 $1,892,620。</p>
</div><h3>What's The Price Target?</h3>
<div class="lb-trans"><h3>價格目標是什麼？</h3>
</div><p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $500.0 to $1600.0 for Eli Lilly during the past quarter.</p>
<div class="lb-trans"><p>分析這些合約的成交量和未平倉合約，似乎大玩家在過去一個季度內關注禮來的價格區間為 $500.0 到 $1600.0。</p>
</div><h3>Analyzing Volume &amp; Open Interest</h3>
<div class="lb-trans"><h3>分析成交量和未平倉合約</h3>
</div><p>In today's trading context, the average open interest for options of Eli Lilly stands at 420.12, with a total volume reaching 954.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Eli Lilly, situated within the strike price corridor from $500.0 to $1600.0, throughout the last 30 days.</p>
<div class="lb-trans"><p>在今天的交易背景下，禮來的期權平均未平倉合約為 420.12，總成交量達到 954.00。附帶的圖表描繪了過去 30 天內禮來高價值交易的看漲和看跌期權的成交量和未平倉合約的變化。</p>
</div><h3>Eli Lilly Option Volume And Open Interest Over Last 30 Days</h3>
<div class="lb-trans"><h3>禮來過去 30 天的期權成交量和未平倉合約</h3>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1767366114_0.png" alt="Options Call Chart" original-src="https://www.benzinga.com/files/images/story/2026/1767366114_0.png"/></p>
<h3>Largest Options Trades Observed:</h3>
<div class="lb-trans"><h3>觀察到的最大期權交易：</h3>
</div><table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/13/26</td>
<td>$13.0</td>
<td>$4.75</td>
<td>$7.65</td>
<td>$910.00</td>
<td>$634.3K</td>
<td align="right">0</td>
<td align="right">805</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$588.0</td>
<td>$580.0</td>
<td>$582.75</td>
<td>$500.00</td>
<td>$291.3K</td>
<td align="right">27</td>
<td align="right">5</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/18/26</td>
<td>$578.05</td>
<td>$571.0</td>
<td>$575.25</td>
<td>$500.00</td>
<td>$287.6K</td>
<td align="right">41</td>
<td align="right">5</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$361.0</td>
<td>$357.4</td>
<td>$361.0</td>
<td>$750.00</td>
<td>$180.5K</td>
<td align="right">376</td>
<td align="right">5</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/18/26</td>
<td>$236.6</td>
<td>$234.6</td>
<td>$236.6</td>
<td>$900.00</td>
<td>$118.3K</td>
<td align="right">162</td>
<td align="right">6</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>符號</strong></th>
<th><strong>看跌/看漲</strong></th>
<th><strong>交易類型</strong></th>
<th><strong>情緒</strong></th>
<th><strong>到期日</strong></th>
<th><strong>賣出價</strong></th>
<th><strong>買入價</strong></th>
<th><strong>價格</strong></th>
<th><strong>行權價</strong></th>
<th><strong>總交易價格</strong></th>
<th align="right"><strong>未平倉合約</strong></th>
<th align="right"><strong>成交量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>看跌</td>
<td>掃描</td>
<td>看漲</td>
<td>02/13/26</td>
<td>$13.0</td>
<td>$4.75</td>
<td>$7.65</td>
<td>$910.00</td>
<td>$634.3K</td>
<td align="right">0</td>
<td align="right">805</td>
</tr>
<tr>
<td>LLY</td>
<td>看漲</td>
<td>交易</td>
<td>看跌</td>
<td>12/18/26</td>
<td>$588.0</td>
<td>$580.0</td>
<td>$582.75</td>
<td>$500.00</td>
<td>$291.3K</td>
<td align="right">27</td>
<td align="right">5</td>
</tr>
<tr>
<td>LLY</td>
<td>看漲</td>
<td>交易</td>
<td>看漲</td>
<td>09/18/26</td>
<td>$578.05</td>
<td>$571.0</td>
<td>$575.25</td>
<td>$500.00</td>
<td>$287.6K</td>
<td align="right">41</td>
<td align="right">5</td>
</tr>
<tr>
<td>LLY</td>
<td>看漲</td>
<td>交易</td>
<td>看漲</td>
<td>01/15/27</td>
<td>$361.0</td>
<td>$357.4</td>
<td>$361.0</td>
<td>$750.00</td>
<td>$180.5K</td>
<td align="right">376</td>
<td align="right">5</td>
</tr>
<tr>
<td>LLY</td>
<td>看漲</td>
<td>交易</td>
<td>看漲</td>
<td>09/18/26</td>
<td>$236.6</td>
<td>$234.6</td>
<td>$236.6</td>
<td>$900.00</td>
<td>$118.3K</td>
<td align="right">162</td>
<td align="right">6</td>
</tr>
</tbody>
</table>
</div><h3>About Eli Lilly</h3>
<div class="lb-trans"><h3>關於禮來</h3>
</div><p>Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.</p>
<div class="lb-trans"><p>禮來是一家專注於神經科學、心血管代謝、癌症和免疫學的製藥公司。禮來的主要產品包括用於癌症的 Verzenio；用於心血管代謝的 Mounjaro、Zepbound、Jardiance、Trulicity、Humalog 和 Humulin；以及用於免疫學的 Taltz 和 Olumiant。</p>
</div><p>In light of the recent options history for Eli Lilly, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<div class="lb-trans"><p>鑑於禮來的近期期權歷史，現在適合關注公司本身。我們旨在探討其當前表現。</p>
</div><h3>Present Market Standing of Eli Lilly</h3>
<div class="lb-trans"><h3>禮來的當前市場狀況</h3>
</div><ul>
<li>With a volume of 331,417, the price of LLY is down -0.98% at $1064.19.</li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 34 days.</li>
</ul>
<div class="lb-trans"><ul>
<li>LLY 的成交量為 331,417，價格下跌 -0.98%，為 $1064.19。</li>
<li>RSI 指標暗示基礎股票可能接近超買狀態。</li>
<li>下一次財報預計將在 34 天后發佈。</li>
</ul>
</div><h3>What The Experts Say On Eli Lilly</h3>
<div class="lb-trans"><h3>專家對禮來的看法</h3>
</div><p>In the last month, 3 experts released ratings on this stock with an average target price of $1222.67.</p>
<div class="lb-trans"><p>在過去一個月中，3 位專家對該股票發佈了評級，平均目標價格為 $1222.67。</p>
</div><p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<div class="lb-trans"><p><strong>在短短 20 天內將 $1000 變成 $1270？</strong></p>
</div><p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.
* Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Eli Lilly with a target price of $1200.
* An analyst from BMO Capital persists with their Outperform rating on Eli Lilly, maintaining a target price of $1200.
* An analyst from B of A Securities persists with their Buy rating on Eli Lilly, maintaining a target price of $1268.</p>
<div class="lb-trans"><p>一位擁有 20 年經驗的期權交易專家揭示了他的單行圖表技術，顯示何時買入和賣出。複製他的交易，平均每 20 天獲得 27% 的利潤。點擊這裏獲取訪問權限。
* 在評估中保持一致，來自富國銀行的分析師對禮來保持超配評級，目標價格為 $1200。
* 來自 BMO Capital 的分析師對禮來保持跑贏大盤評級，目標價格為 $1200。
* 來自美國銀行證券的分析師對禮來保持買入評級，目標價格為 $1268。</p>
</div><p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<div class="lb-trans"><p>期權是一種比僅交易股票更具風險的資產，但它們具有更高的利潤潛力。嚴肅的期權交易者通過每天學習、逐步進出交易、關注多個指標以及密切關注市場來管理這種風險。</p>
</div><p>If you want to stay updated on the latest options trades for Eli Lilly, Benzinga Pro gives you real-time options trades alerts.</p>
<div class="lb-trans"><p>如果您想隨時瞭解禮來的最新期權交易，Benzinga Pro 為您提供實時期權交易警報。</p>
</div>

禮來最新期權趨勢的幕後揭秘